Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-NEW: Adaptive weight loss in breast cancer survivors
NCT04499950Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of naltrexone + bupropion in obesity (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of Patients With 5 Percent Weight Loss in SLOW-BWL at 6 months. Started Feb 2021; status: completed.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04499950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499950.